Breaking News Instant updates and real-time market news.

ELAN

Elanco

$29.33

-0.225 (-0.76%)

, CRMD

CorMedix

$2.66

0.53 (24.88%)

08:45
02/13/19
02/13
08:45
02/13/19
08:45

Largest borrow rate increases among liquid names

Latest data shows the largest indicative borrow rate increases among liquid option names include: Elanco Animal Health (ELAN) 15.05% +7.96, CorMedix (CRMD) 31.43% +0.47, Sonos (SONO) 3.67% +0.21, Midstates Petroleum (MPO) 1.89% +0.18, Overstock com (OSTK) 10.74% +0.17, Coty (COTY) 0.42% +0.07, AngloGold (AU) 0.48% +0.04, Restoration Hardware (RH) 0.85% +0.02, British Pound Sterling (FXB) 5.56% +0.02, and Deutsche Bank (DB) 0.37% +0.02.

ELAN

Elanco

$29.33

-0.225 (-0.76%)

CRMD

CorMedix

$2.66

0.53 (24.88%)

SONO

Sonos

$11.20

0.2 (1.82%)

MPO

Midstates Petroleum

$9.94

0.12 (1.22%)

OSTK

Overstock.com

$19.04

0.64 (3.48%)

COTY

Coty

$10.87

1.2 (12.41%)

AU

AngloGold

$13.43

0.17 (1.28%)

RH

RH

$139.15

7.88 (6.00%)

DB

Deutsche Bank

$8.54

0.22 (2.64%)

  • 03

    Mar

ELAN Elanco
$29.33

-0.225 (-0.76%)

01/23/19
UBSW
01/23/19
INITIATION
Target $29
UBSW
Sell
Elanco initiated with a Sell at UBS
UBS analyst Navin Jacob started Elanco Animal Health with a Sell rating and $29 price target. The company has solid fundamentals, but the stock price and long-term consensus estimates are "too far ahead" of what survey work suggests, Jacob tells investors in a research note.
02/12/19
02/12/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Viavi (VIAV) initiated with an Outperform at Northland. 2. CECO Environmental (CECE) initiated with a Buy at B. Riley FBR. 3. Tencent Music (TME) initiated with an Outperform at Macquarie. 4. Enable Midstream (ENBL) initiated with a Neutral at Mizuho. 5. Elanco (ELAN) initiated with a Market Perform at William Blair. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
02/11/19
WBLR
02/11/19
INITIATION
WBLR
Market Perform
Elanco initiated with a Market Perform at William Blair
William Blair analyst John Kreger started Elanco Animal Health with a Market Perform rating.
01/15/19
01/15/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. StoneCo (STNE) initiated with a Buy at BofA/Merrill. 2. Southwest Gas (SWX) initiated with a Market Perform at Wells Fargo. 3. Luna Innovations (LUNA) initiated with a Buy at B. Riley FBR. 4. Dell Technologies (DELL) initiated with a Neutral at UBS. 5. Elanco (ELAN) initiated with a Buy at Argus. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
CRMD CorMedix
$2.66

0.53 (24.88%)

12/06/18
ROTH
12/06/18
INITIATION
Target $6
ROTH
Buy
CorMedix initiated with a Buy at Roth Capital
Roth Capital analyst Jerry Isaacson started coverage of CorMedix with a Buy rating and $6 price target. The analyst notes that the company is developing Neutrolin for the prevention of catheter-related blood stream infections in patients with central venous catheters, and believes there is a large market opportunity for Neutrolin in multiple patient populations. CorMedix has Fast-Track designation from the FDA and QIDP designation, leading to 10.5 years of market exclusivity, he adds.
12/06/18
12/06/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. LG Display (LPL) initiated with a Buy at Citi. 2. Twitter (TWTR) and Alphabet (GOOG, GOOGL) were initiated with a Buy at Guggenheim, while Snap (SNAP) and Facebook (FB) were initiated with a Neutral. 3. Apache (APA) initiated with an Overweight at Stephens. 4. CorMedix (CRMD) initiated with a Buy at Roth Capital. 5. Protagonist Therapeutics (PTGX) initiated with a Buy at Nomura Instinet. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
07/26/18
HCWC
07/26/18
NO CHANGE
Target $3
HCWC
Buy
CorMedix price target raised to $3 from $2 at H.C. Wainwright
H.C. Wainwright analyst Raghuram Selvaraju raised his price target for CorMedix to $3 saying the Neutrolin interim readout delivered a "home run." The analyst sees a possibility now for Neutrolin to be filed before the end of this year and to be approved in 2019, versus his original assumption that the drug would not enter the U.S. market prior to 2020. Further, the news of the clear efficacy signal in the LOCK-IT-100 study could meaningfully accelerate ex-U.S. sales of the product, the analyst adds. He reiterates a Buy rating on CorMedix.
12/12/18
HCWC
12/12/18
NO CHANGE
Target $3.5
HCWC
Buy
CorMedix price target raised to $3.50 from $3 at H.C. Wainwright
H.C. Wainwright analyst Raghuram Selvaraju raised his price target for CorMedix to $3.50 and reiterates a Buy rating on the shares. The analyst continues to believe that it is possible that the FDA would agree to an accelerated filing pathway for Neutrolin because of the unmet nature of the medical need with respect to catheter-related bloodstream infections and the power of the previously-reported LOCK-IT-100 interim analysis. CorMedix management have indicated that progress continues to be made towards the finalization of a New Drug Application filing on Neutrolin, Selvaraju tells investors in a research note.
SONO Sonos
$11.20

0.2 (1.82%)

02/07/19
STFL
02/07/19
NO CHANGE
Target $14
STFL
Hold
Sonos price target lowered to $14 from $20 at Stifel
Stifel analyst Matthew Sheerin said Sonos management outlined several near-term issues, including weaker than expected sales late in the quarter, soft demand in Europe and the delayed launch of IKEA products with Sonos speakers. While the company maintained its FY19 targets for sales and EBITDA growth, he is cutting his estimates to the low end of the company's ranges due to lack of visibility and competition concerns. Sheerin lowered his price target on Sonos shares to $14 from $20 and keeps a Hold rating on the stock.
02/07/19
MSCO
02/07/19
NO CHANGE
Target $15
MSCO
Overweight
Sonos pullback a buying opportunity, says Morgan Stanley
Morgan Stanley analyst Yuuji Anderson said he would be a buyer of Sonos on the stock's post-earnings pullback, citing what he views as its underappreciated opportunity in Amp and new passive speakers as well as its better than expected operating leverage. While high channel inventory exiting December is disappointing, it should be manageable with new product impact ramping through 2019, said Anderson, who noted that January sell-through is tracking ahead of plan. He maintains an Overweight rating and $15 price target on Sonos shares.
02/04/19
JPMS
02/04/19
NO CHANGE
Target $228
JPMS
Overweight
Activision, Sonos, Netflix offer best strategic fits for Apple, says JPMorgan
Despite Apple (AAPL) itself offering no comments on the subject or giving any indication to investors of its intentions, potential acquisition targets for the company have been widely discussed in press reports on a regular basis, JPMorgan analyst Samik Chatterjee tells investors in a research note. The speculation has included a wide range of industries, from automobile manufacturers, like Tesla (TSLA), to information platforms, like Twitter (TWTR), adds the analyst. He believes the speculation has likely in part been driven by the $130B of net cash on Apple's balance sheet. Chatterjee finds three industries to be of the most strategic value to Apple for potential deals: Video gaming, smart home speaker and video content. These areas provide potential growth opportunities to leverage Apple's services over a wider installed base, says the analyst. In video gaming, he sees Activision Blizzard (ATVI) as being the best strategic fit for Apple. In smart home speaker, Chatterjee believes Sonos (SONO) offers the best strategic of the names mentioned in the press. And in video content, the analyst views Netflix (NFLX) as the best strategic fit, although he "appreciates a combination is less likely as Netflix is unlikely to be a seller for a modest premium."
01/28/19
01/28/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Zynga (ZNGA) upgraded to Overweight from Sector Weight at KeyBanc with analyst Evan Wingren saying he likes the tactical setup as margin targets for FY19 have been established, the pipeline of new games is based on high quality IP, and he has confidence in the management team in place given its track record since joining. 2. GrubHub (GRUB) and Wayfair (W) were upgraded to Outperform from Neutral at Credit Suisse. 3. Logitech (LOGI) upgraded to Buy from Neutral at Goldman Sachs with analyst Mohammed Moawalla saying the stock has underperformed the Europe Technology group by 17% in last six months despite "strong management execution and continuing secular growth avenues." 4. Sonos (SONO) upgraded to Overweight from Equal Weight at Morgan Stanley with analyst Yuuji Anderson saying he has become more confident that new products will drive growth and margin expansion. 5. Synnex (SNX) upgraded to Buy from Neutral at Citi with analyst Tim Yang saying Synnex continues to increase its value-add services exposure, which should support sustainable margin expansion in the next two years. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
MPO Midstates Petroleum
$9.94

0.12 (1.22%)

OSTK Overstock.com
$19.04

0.64 (3.48%)

12/21/18
DADA
12/21/18
NO CHANGE
Target $58
DADA
Buy
DA Davidson sees encouraging signs for Overstock despite GSR disappointment
DA Davidson analyst Tom Forte said while he recognizes the recent disappointment regarding Overstock's inability to close its transactions with GSR Ventures, he is also seeing encouraging signs for the company's blockchain-related investments. "Lost in the disappointment of Monday" was the announcement that GSR Ventures and tZERO intend to work together to tokenize cobalt, which he sees as one example of potentially many regarding its ability to play an instrumental role in the creation and trading of tokens, Forte tells investors. He reiterates a Buy rating and $58 price target on Overstock shares and recommends purchasing at current levels, noting that his target includes a $31 per share valuation for its legacy home e-commerce business and $27 for its Medici Ventures portfolio of 19 blockchain companies, most of that being attributable to tZERO.
12/18/18
DADA
12/18/18
NO CHANGE
Target $58
DADA
Buy
Overstock.com price target lowered to $58 from $112 at DA Davidson
DA Davidson analyst Tom Forte slashed his price target on Overstock.com to $58 after the company's disclosure to investors that it was unable to finalize its GSR Ventures transaction by its mid-December target yesterday, pushing that deadline to February of next year. The analyst notes that investors responded to this management stumble by sending the stock price down over 20% from what he sees as "already depressed levels". Forte still keeps his Buy rating on Overstock.com, but states that his new valuation methodology is based on more of a "crawl, walk, run approach", even though he still values the company's 80% tZero holdings at a $1B valuation that equates to $27 per share and its retail business at 31 per share.
01/25/19
DADA
01/25/19
NO CHANGE
Target $58
DADA
Buy
Overstock.com's tZERO an 'incredibly valuable asset,' says DA Davidson
DA Davidson analyst Tom Forte reiterated a Buy rating and $58 price target on Overstock.com. In a research note to investors, Forte says he continues to view tZERO as an "incredibly valuable asset" and sees that the secondary trading of security tokens is an "important" accomplishment on the way to popularizing the tokenization of assets.
02/12/19
DADA
02/12/19
NO CHANGE
Target $60
DADA
Underperform
DA Davidson reiterates $60 target on Wayfair citing Amazon 'encroachment'
In a research earlier today titled "Encroachment Is a 5-Yard Penalty," DA Davidson analyst Tom Forte reiterated an Underperform rating on Wayfair with a $60 12-18 month price target. The stock in morning trading is up 1% to $120.89. Amazon.com (AMZN) announced yesterday that it was launching two private-label furniture brands in the U.K., Forte wrote to investors. The analyst sees the news as "yet another indication" of Amazon's intent to expand its efforts in the home category, including furniture. Yesterday's announcement follows Amazon's decision last December to lower third-party selling fees for the furniture category, the analyst points out. Forte views Amazon's efforts to ramp its sales in the home category as an increasing threat for Wayfair. Further, the analyst is monitoring the potential sale of Overstock's (OSTK) legacy home e-commerce business, as he thinks a sale to a large bricks and mortar retailer could also result in additional competition for Wayfair.
COTY Coty
$10.87

1.2 (12.41%)

11/15/18
BMOC
11/15/18
UPGRADE
Target $12
BMOC
Outperform
Coty upgraded to Outperform from Market Perform at BMO Capital
BMO Capital analyst Shannon Coyne upgraded Coty to Outperform from Market Perform and kept her price target at $12. The analyst says that her downgrade in August was driven by concerns around the company's supply chain issues, but believes that these factors have now been fully priced in after the management withdrew its guidance and consensus earnings have been pulled back by about 30%. With a 30% decline in the stock price over the past 10 weeks, Coyne states that the risk-reward on shares of Coty is now "compelling".
11/15/18
11/15/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Mylan (MYL) upgraded to Buy from Hold at Argus with analyst Jasper Hellweg saying the stock appears to be close to an inflection after several quarters of underperformance. 2. CopyTele (COPY) upgraded to Outperform from Market Perform at BMO Capital. 3. Voyager Therapeutics (VYGR) upgraded to Strong Buy from Outperform at Raymond James. 4. Athenex (ATNX) upgraded to Overweight from Neutral at JPMorgan with analyst Leon Chik saying more clinical data and progress in new drug trials should boost investor sentiment in 2019. 5. Coty (COTY) upgraded to Outperform from Market Perform at BMO Capital with analyst Shannon Coyne saying that her downgrade in August was driven by concerns around the company's supply chain issues, but believes that these factors have now been fully priced in after the management withdrew its guidance and consensus earnings have been pulled back by about 30%. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
01/04/19
JPMS
01/04/19
UPGRADE
Target $7
JPMS
Neutral
Coty upgraded to Neutral from Underweight at JPMorgan
JPMorgan analyst Andrea Teixeira upgraded Coty to Neutral with a $7 price target. The analyst's sum-of-the-parts analysis indicates Coty's valuation is "flushed out" at current levels. Teixeira, however, still sees potential downside to consensus estimates.
02/11/19
JPMS
02/11/19
NO CHANGE
Target $10
JPMS
Neutral
Coty price target raised to $10 from $7 at JPMorgan
JPMorgan analyst Andrea Teixeira raised her price target for Coty to $10 following the company's Q2 beat and keeps a Neutral rating on the shares. The analyst found "renewed energy from new management encouraging," but points out there there were "no major financial strings or timing attached to the turnaround at this point." Teixeira sees "massive execution risks" for the company, which keeps her on the sidelines post Friday's 32% "relief rally."
AU AngloGold
$13.43

0.17 (1.28%)

08/28/18
08/28/18
DOWNGRADE

Underperform
Macquarie says avoid deep level operators, cuts Harmony, Sibanye to Underperform
As previously reported, Macquarie analyst Yatish Chowthee downgraded Harmony Gold (HMY) and Sibanye Gold (SBGL), both to Underperform from Neutral, citing the inflationary headwinds facing the South African gold mining sector, particularly those faced by the deep level operators. He favors companies with a geographically diverse portfolio mix and views investments in the sector as better suited to the short-to-medium term given the level of volatility exhibited with gold equities, Chowthee tells investors. However, he maintain an Outperform rating on AngloGold (AU).
12/10/18
BMOC
12/10/18
INITIATION
Target $11
BMOC
Market Perform
AngloGold initiated with a Market Perform at BMO Capital
BMO Capital analyst Andrew Kaip initiated AngloGold with a Market Perform rating and a price target of $11. The analyst states that while the company's outlook has improved, its stock price has also risen about 40% relative to peers over the past 4 months and has now reached a valuation multiple that is comparable to its group. Kaip adds that he will look for further indications of mind life improvement from the new CEO Kelvin Dushnisky along with solid execution at the Obuasi mine after the executive's decision to approve the redevelopment, which has likely stabilized the company's annual production in the 3.3M oz range into the middle of next decade.
11/06/18
SBSH
11/06/18
DOWNGRADE
SBSH
Sell
AngloGold downgraded to Sell from Neutral at Citi
Citi analyst Johann Steyn downgraded AngloGold to Sell saying the shares are expensive following the recent rally. The analyst thinks the stock has rallied too far on limited fundamental news.
09/18/18
RBCM
09/18/18
DOWNGRADE
RBCM
Sector Perform
AngloGold downgraded to Sector Perform from Outperform at RBC Capital
RBC Capital analyst James Bell downgraded AngloGold (AU) to Sector Perform from Outperform and lowered his price target to ZAR13,000 from ZAR13,200. The analyst says the "large diversified gold miner business is under pressure" and needs to be addressed, but adds that the company's new CEO Kevin Dushinsky is up to the task. Bell adds that AngloGold's valuation is less attractive than some of its South Africa peers like Gold Fields (GFI).
RH RH
$139.15

7.88 (6.00%)

12/04/18
STFL
12/04/18
NO CHANGE
Target $180
STFL
Buy
RH price target raised to $180 from $150 at Stifel
Stifel analyst John Baugh noted that RH's Q3 results, as well as its 2018 and 2019 guidance, were above consensus, stating that he continues to be impressed with the company's ability to distinguish itself in the highly competitive retail industry. Given that investors have been increasingly bearish on the furnishings space, Baugh said he thinks RH's results will be well received. He maintains a Buy rating on RH shares and raised his price target on the stock to $180 from $150 based on his increase FY19 EPS estimate of $9.99.
12/04/18
KEYB
12/04/18
NO CHANGE
Target $180
KEYB
Overweight
RH price target raised to $180 from $166 at KeyBanc
KeyBanc analyst Bradley Thomas raised his price target for RH to $180 from $166, citing "strong" Q3 results. The analyst continues to see margins driving EPS upside and remains very positive on the long-term growth story ahead. He reiterates an Overweight rating on the shares.
01/07/19
KEYB
01/07/19
DOWNGRADE
KEYB
Sector Weight
RH downgraded to Sector Weight from Overweight at KeyBanc
01/07/19
KEYB
01/07/19
DOWNGRADE
KEYB
Sector Weight
RH downgraded to Sector Weight at KeyBanc
As previously reported, KeyBanc analyst Bradley Thomas downgraded RH to Sector Weight from Overweight as he believes Hardlines investors need to be increasingly selective in 2019. The analyst remains most negative on Home Furnishings from a competitive and cyclical perspective.
DB Deutsche Bank
$8.54

0.22 (2.64%)

08/10/18
MSCO
08/10/18
DOWNGRADE
MSCO
Underweight
Deutsche Bank downgraded to Underweight from Equal Weight at Morgan Stanley
08/10/18
08/10/18
DOWNGRADE

Underweight
Morgan Stanley cuts Deutsche Bank to Underweight on limited top-line visibility
As previously reported, Morgan Stanley analyst Magdalena Stoklosa downgraded Deutsche Bank to Underweight from Equal Weight, stating that while she gives management "full credit" for its cost cutting efforts, it is hard to have any visibility on the top line. She assumes 2018-20 revenue CAGR of just 1.5%, which is below the average for Eurozone banks and below managements target of 4%. While recognizing the risk of downgrading Deutsche Bank "at the bottom," Stoklosa sees current conditions as unlikely to be conducive to a near-term re-rating, she tells investors. She has an EUR9 target on the bank's shares.
08/13/18
BOFA
08/13/18
DOWNGRADE
Target $9
BOFA
Underperform
Deutsche Bank downgraded to Underperform from Neutral at BofA/Merrill
BofA/Merrill analyst Andrew Stimpson downgraded Deutsche Bank to Underperform from Neutral saying he expects the earnings downgrade cycle to continue given CIB revenue headwinds.
06/01/18
RBCM
06/01/18
DOWNGRADE
RBCM
Underperform
Deutsche Bank downgraded to Underperform from Sector Perform at RBC Capital

TODAY'S FREE FLY STORIES

IRM

Iron Mountain

$35.51

0.12 (0.34%)

10:18
02/20/19
02/20
10:18
02/20/19
10:18
Recommendations
Iron Mountain analyst commentary  »

Iron Mountain price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

10:17
02/20/19
02/20
10:17
02/20/19
10:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HUM

Humana

$306.68

1.33 (0.44%)

10:16
02/20/19
02/20
10:16
02/20/19
10:16
Hot Stocks
Humana, PatientPing announce agreement to improve care coordination »

PatientPing announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Mar

  • 19

    Mar

$NYE

NYSE Market Internals

$0.00

(0.00%)

10:16
02/20/19
02/20
10:16
02/20/19
10:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KOD

Kodiak Sciences

$7.51

0.64 (9.32%)

, VEEV

Veeva

$120.49

0.1 (0.08%)

10:16
02/20/19
02/20
10:16
02/20/19
10:16
Initiation
Fly Intel: Top five analyst initiations »

Catch up on today's…

KOD

Kodiak Sciences

$7.51

0.64 (9.32%)

VEEV

Veeva

$120.49

0.1 (0.08%)

AGIO

Agios Pharmaceuticals

$58.78

1.07 (1.85%)

KIDS

OrthoPediatrics

$38.69

1.31 (3.50%)

FIXX

Homology Medicines

$24.90

0.87 (3.62%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

  • 21

    Feb

  • 21

    Feb

  • 22

    Feb

  • 25

    Feb

  • 26

    Feb

  • 26

    Feb

  • 13

    Mar

  • 26

    Mar

  • 27

    Mar

  • 10

    Apr

  • 11

    Apr

  • 21

    Jun

CVS

CVS Health

$63.82

-6.1 (-8.72%)

, LUV

Southwest

$54.63

-3.03 (-5.25%)

10:16
02/20/19
02/20
10:16
02/20/19
10:16
Downgrade
Fly Intel: Top five analyst downgrades »

Catch up on today's…

CVS

CVS Health

$63.82

-6.1 (-8.72%)

LUV

Southwest

$54.63

-3.03 (-5.25%)

SCHW

Charles Schwab

$45.95

-1.11 (-2.36%)

ETFC

E-Trade

$48.05

-0.61 (-1.25%)

PANW

Palo Alto Networks

$228.77

-1.42 (-0.62%)

TEVA

Teva

$17.40

-0.61 (-3.39%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

  • 20

    Feb

  • 20

    Feb

  • 22

    Feb

  • 23

    Feb

  • 23

    Feb

  • 25

    Feb

  • 25

    Feb

  • 26

    Feb

  • 26

    Feb

  • 27

    Feb

  • 27

    Feb

  • 04

    Mar

  • 05

    Mar

  • 12

    Mar

IPSEY

Ipsen

$0.00

(0.00%)

, CS

Credit Suisse

$11.91

0.005 (0.04%)

10:16
02/20/19
02/20
10:16
02/20/19
10:16
Upgrade
Fly Intel: Top five analyst upgrades »

Catch up on today's…

IPSEY

Ipsen

$0.00

(0.00%)

CS

Credit Suisse

$11.91

0.005 (0.04%)

AXL

American Axle

$16.92

0.32 (1.93%)

DO

Diamond Offshore

$10.65

0.36 (3.50%)

RIG

Transocean

$8.86

0.12 (1.37%)

PFE

Pfizer

$42.25

-0.33 (-0.78%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

  • 03

    Mar

  • 12

    Mar

  • 13

    Mar

  • 14

    Mar

  • 18

    May

  • 22

    May

LUV

Southwest

$54.67

-2.99 (-5.19%)

, ALK

Alaska Air

$63.60

-0.95 (-1.47%)

10:15
02/20/19
02/20
10:15
02/20/19
10:15
On The Fly
Goldman Sachs says sell Southwest as airline cuts guidance »

Shares of Southwest (LUV)…

LUV

Southwest

$54.67

-2.99 (-5.19%)

ALK

Alaska Air

$63.60

-0.95 (-1.47%)

AAL

American Airlines

$34.96

-0.5 (-1.41%)

UAL

United Continental

$87.68

-1.53 (-1.72%)

DAL

Delta Air Lines

$50.89

-0.93 (-1.79%)

JBLU

JetBlue

$17.68

-0.24 (-1.34%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

  • 22

    Feb

  • 25

    Feb

  • 04

    Mar

10:15
02/20/19
02/20
10:15
02/20/19
10:15
General news
FX Action: USD-CAD »

FX Action: USD-CAD traded…

DWDP

DowDuPont

$55.00

0.4 (0.73%)

10:10
02/20/19
02/20
10:10
02/20/19
10:10
Options
Put buyers in DowDuPont weekly options »

Put buyers in DowDuPont…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

  • 25

    Feb

  • 27

    Feb

  • 04

    Mar

  • 04

    Mar

  • 13

    Mar

  • 28

    May

MGNX

MacroGenics

$21.98

-0.2 (-0.90%)

, XNCR

Xencor

$33.00

-3.18 (-8.79%)

10:09
02/20/19
02/20
10:09
02/20/19
10:09
Recommendations
MacroGenics, Xencor analyst commentary  »

Xencor hold supports…

MGNX

MacroGenics

$21.98

-0.2 (-0.90%)

XNCR

Xencor

$33.00

-3.18 (-8.79%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

  • 25

    Feb

  • 26

    Feb

  • 27

    Feb

  • 27

    Feb

MBIO

Mustang Bio

$4.15

(0.00%)

, FBIO

Fortress Biotech

$2.15

-0.01 (-0.46%)

10:05
02/20/19
02/20
10:05
02/20/19
10:05
Recommendations
Mustang Bio, Fortress Biotech analyst commentary  »

Mustang Bio partnership…

MBIO

Mustang Bio

$4.15

(0.00%)

FBIO

Fortress Biotech

$2.15

-0.01 (-0.46%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TRMB

Trimble

$39.47

0.1 (0.25%)

, DGII

Digi International

$13.40

0.04 (0.30%)

10:03
02/20/19
02/20
10:03
02/20/19
10:03
Hot Stocks
Trimble, Digi collaborate to provide fleets with cold chain compliance solution »

Trimble (TRMB) announced…

TRMB

Trimble

$39.47

0.1 (0.25%)

DGII

Digi International

$13.40

0.04 (0.30%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

  • 05

    Mar

  • 14

    Mar

WWW

Wolverine World Wide

$35.90

-3.6 (-9.11%)

10:00
02/20/19
02/20
10:00
02/20/19
10:00
Hot Stocks
Wolverine World Wide falls -9.1% »

Wolverine World Wide is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

  • 20

    Feb

LC

LendingClub

$3.27

-0.355 (-9.81%)

10:00
02/20/19
02/20
10:00
02/20/19
10:00
Hot Stocks
LendingClub falls -10.4% »

LendingClub is down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

OMI

Owens & Minor

$6.46

-1.48 (-18.64%)

10:00
02/20/19
02/20
10:00
02/20/19
10:00
Hot Stocks
Owens & Minor falls -18.5% »

Owens & Minor is down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

  • 20

    Feb

NVTA

Invitae

$18.07

1.58 (9.58%)

10:00
02/20/19
02/20
10:00
02/20/19
10:00
Hot Stocks
Invitae rises 9.0% »

Invitae is up 9.0%, or…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 27

    Feb

BDC

Belden

$62.43

5.79 (10.22%)

10:00
02/20/19
02/20
10:00
02/20/19
10:00
Hot Stocks
Belden rises 9.8% »

Belden is up 9.8%, or…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

  • 20

    Feb

  • 13

    May

  • 14

    May

  • 15

    May

F

Ford

$8.94

0.11 (1.25%)

10:00
02/20/19
02/20
10:00
02/20/19
10:00
Options
Put buyers in Ford shortly after the opening bell Wednesday »

Put buyers in Ford…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 24

    Jul

  • 23

    Oct

DVN

Devon Energy

$32.15

3.84 (13.56%)

10:00
02/20/19
02/20
10:00
02/20/19
10:00
Hot Stocks
Devon Energy rises 13.6% »

Devon Energy is up 13.6%,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

  • 20

    Feb

  • 27

    Feb

  • 28

    Feb

  • 22

    May

TSLA

Tesla

$304.81

-0.75 (-0.25%)

09:58
02/20/19
02/20
09:58
02/20/19
09:58
On The Fly
Tesla drops as general counsel leaves after just two months »

Shares of Tesla (TSLA)…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

  • 21

    Feb

  • 25

    Feb

  • 18

    Mar

  • 19

    Mar

ET

Energy Transfer LP

$15.64

(0.00%)

09:55
02/20/19
02/20
09:55
02/20/19
09:55
Options
Energy Transfer put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

GRMN

Garmin

$79.73

8.77 (12.36%)

, DVN

Devon Energy

$31.90

3.59 (12.68%)

09:55
02/20/19
02/20
09:55
02/20/19
09:55
Options
Early notable gainers among liquid option names on February 20th »

Notable gainers among…

GRMN

Garmin

$79.73

8.77 (12.36%)

DVN

Devon Energy

$31.90

3.59 (12.68%)

CF

CF Industries

$43.09

1.07 (2.55%)

HST

Host Hotels

$18.93

0.41 (2.21%)

PCG

PG&E

$18.03

0.28 (1.58%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

  • 20

    Feb

  • 20

    Feb

  • 20

    Feb

  • 20

    Feb

  • 20

    Feb

  • 25

    Feb

  • 27

    Feb

  • 27

    Feb

  • 28

    Feb

  • 22

    May

  • 28

    May

09:55
02/20/19
02/20
09:55
02/20/19
09:55
Conference/Events
UBS technology analyst to hold an analyst/industry conference call »

Technology Analyst…

09:55
02/20/19
02/20
09:55
02/20/19
09:55
Conference/Events
Wedbush digital media analyst to hold an analyst/industry conference call »

Digital Media Analyst…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.